GIM
ANAB icon

Glenmede Investment Management’s AnaptysBio ANAB Stock Holding History

Glenmede Investment Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,546
Closed -$168K – 1448
2025
Q2 		$168K Buy
+7,546
New +$158K ﹤0.01% 1255

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Glenmede Investment Management's ANAB Position: Q3 2025 in Review

Glenmede Investment Management sold out of AnaptysBio (ANAB) in Q3 2025, closing a stake of 7,546 shares — an estimated $168K sold.

Glenmede Investment Management first reported a position in ANAB in Q2 2025 and held it in 1 quarter. The position peaked at $168K in Q2 2025. 166 funds tracked by Wall St. Rank hold ANAB as of Q3 2025.

  • Glenmede Investment Management reported no remaining AnaptysBio position as of Q3 2025 after selling out during the quarter.
  • Glenmede Investment Management sold 7,546 AnaptysBio shares in Q3 2025, an estimated $168K.
  • Glenmede Investment Management first reported a position in AnaptysBio in Q2 2025 and held it in 1 quarter.
  • Glenmede Investment Management's AnaptysBio position peaked at $168K in Q2 2025.
  • 166 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.